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Background: Effective management of major depressive disorder often includes the long-term 
use of multiple medications, and the longer-term utility and safety of adjunctive aripiprazole 
has not been evaluated in a controlled setting.
Patients and methods: Patients (n = 706) completing one of two 14-week double-blind 
studies of aripiprazole augmentation, as well as de novo patients (n = 296) nonresponsive to 
current antidepressant therapy, were enrolled in this open-label study. Patients received open-
label aripiprazole for up to 52 weeks.
Results: Open-label treatment was completed by 323 patients (32.2%). At endpoint (n = 987), 
the mean dose of aripiprazole was 10.1 mg/day. Common (.15% of patients) spontaneously 
reported adverse events were akathisia (26.2%), fatigue (18.0%), and weight gain (17.1%). The 
incidence of serious adverse events was 4.0%. Four spontaneous reports of possible tardive 
dyskinesia were submitted (0.4%); all resolved within 45 days of drug discontinuation. Mean 
weight change was 4.4 kg; 36.6% experienced $7% increase in weight from baseline (observed 
case analysis, n = 303). No clinically relevant changes in other metabolic parameters were seen. 
At the end of open-label treatment, 221 patients (69.7%) had a Clinical Global Impression-
Severity of Illness score of 1 (not at all ill) or 2 (borderline ill).
Conclusion: Long-term adjunctive aripiprazole therapy was well tolerated with an acceptable 
long-term safety and tolerability profile in patients with major depressive disorder who had not 
responded to treatment with one or more antidepressant therapies. Clinically significant weight 
gain was observed in about one-third of patients. Overall, the adverse event profile was consistent 
with that reported in the short-term trials and readily managed clinically.
Keywords: adjunctive aripiprazole, antidepressant therapy, major depressive disorder, long-
term safety and tolerability
Introduction
More than 60% of patients with major depressive disorder do not achieve remission 
following treatment with an adequate course of at least one antidepressant.1,2 For 
patients who do not obtain adequate benefit from antidepressant therapy, adjunctive 
therapy with an atypical antipsychotic is one treatment option.3,4
Aripiprazole, a partial agonist at the D2/D3 receptor and 5-HT1A receptor, and a full 
antagonist at the 5-HT2A receptor, is approved for use in the US as a treatment adjunctive 
to antidepressant therapy in adults with major depressive disorder. Results from three 
large, multicenter, randomized, double-blind, placebo-controlled trials demonstrated 
that aripiprazole treatment is effective and well tolerated as treatment adjunctive 
to antidepressant therapy in subjects with an inadequate response to a   prospective Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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eight-week trial of the same antidepressant therapy and at 
least one historical antidepressant therapy trial.5–7 In these 
short-term major depressive disorder trials, adjunctive 
aripiprazole demonstrated a safety and tolerability profile 
similar to that seen in monotherapy studies of patients with 
schizophrenia8 or bipolar mania.9 Furthermore, the rates of 
discontinuation due to adverse events were low.5–7 However, 
in order to prevent recurrence of major depressive episodes, 
patients with major depressive disorder may require long-
term maintenance therapy. The utility, safety, and tolerability 
of long-term adjunctive aripiprazole therapy have not yet 
been studied.
The introduction of any new treatment strategy requires 
extra vigilance with regard to safety, particularly for combi-
nation treatment strategies where each class of medication 
has potential side effects.10,11 Furthermore, augmentation 
of standard antidepressant therapies has the potential to 
induce, or even exacerbate, adverse events. Adverse events 
commonly seen with atypical antipsychotic monotherapy 
include weight gain, sedation, extrapyramidal symptoms, 
metabolic disturbances (eg, diabetes and hyperlipidemia) 
and hyperprolactinemia, although the risk varies between 
agents.12–14 Understanding the longer-term safety and toler-
ability profile of adjunctive treatment is important in order 
to optimize clinical management and promote long-term 
adherence when appropriate.
This paper reports the findings from a 52-week, open-
label trial that assessed the long-term safety and tolerability of 
aripiprazole adjunctive to antidepressant therapy. Assessment 
of tolerability was the primary objective of this study, and 
was evaluated by spontaneous reporting of adverse events, 
assessment of extrapyramidal symptoms using objective rat-
ing scales, and assessment of changes in body weight, fasting 
plasma lipids, and glucose levels. Specific efficacy findings 
from this long-term, open-label safety extension phase are 
also presented. Eligible patients included those who had been 
previously treated with adjunctive aripiprazole or placebo in 
two of the previous short-term trials,5,6 as well as de novo 
subjects with a documented inadequate response to standard 
antidepressant therapy.
Methods
study design and patients
This report includes data from a 52-week, open-label study 
to assess the long-term safety and tolerability of aripiprazole 
adjunctive to antidepressant therapy. In this reporting, dura-
tion of adjunctive aripiprazole dosing includes any exposure 
a patient may have received in the short-term trials, and any 
adverse events that may have emerged upon initiation of 
adjunctive aripiprazole treatment in those trials.
This study enrolled patients from two sources, ie, patients 
who had previously been enrolled in two 14-week, double-
blind, placebo-controlled trials5,6 (rollover patients), as well 
as de novo patients. Rollover patients entering this open-label 
study from the previously completed 14-week trials had to 
have had an inadequate response to a prospective antidepres-
sant therapy treatment (venlafaxine, escitalopram, paroxetine, 
fluoxetine, or sertraline) at week 8 and have completed an 
additional six-week, randomized, double-blind period with 
adjunctive aripiprazole (aripiprazole rollover) or placebo 
(placebo rollover) treatment. Patients who had been anti-
depressant therapy responders at week 8, and thus were not 
eligible for randomization, could enter the open-label phase if 
they did not meet criteria for remission (Montgomery-Åsberg 
Depression Rating Scale [MADRS]15 #10) at week 14.
The patients were men and women, aged 18 years and 
older, who met the Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition-Text Revision (DSM-IV-TR) 
criteria for a major depressive episode.16 All rollover patients 
entering this open-label study met the following inclusion 
criteria at the time of entry into the previously completed 
double-blind study: they were required to have had a major 
depressive episode that had lasted at least eight weeks prior 
to inclusion with an inadequate response, defined as a ,50% 
reduction in depressive symptoms severity, as assessed by 
the Massachusetts General Hospital Antidepressant Treat-
ment Response Questionnaire [ATRQ]17 to at least one but 
no more than three antidepressant therapy trials (each of at 
least six weeks’ duration and at an adequate dose). Following 
screening, patients could then enter an eight-week prospec-
tive antidepressant treatment phase if they had a 17-item 
Hamilton Rating Scale for Depression (HAM-D-17)18 total 
score $18 and could continue into the double-blind treatment 
phase if they had a HAM-D-17 total score that represented 
a ,50% reduction in symptoms during prospective treat-
ment, a HAMD-17 total score $14, and a Clinical Global 
Impressions-Improvement (CGI-I)19 score $3. For entry into 
this long-term study, patients were also required to have the 
potential to benefit from further pharmacological adjust-
ments (administration of adjunctive aripiprazole) based on 
the opinion of the investigator.
Inclusion criteria for de novo patients were similar 
to those for rollover patients, and included a duration of 
current depressive episode of at least eight weeks, an inad-
equate response indicated by a ,50% improvement on the 
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Response Questionnaire to at least one but no more than four 
antidepressant therapy trials (each of at least six weeks’ dura-
tion and at an adequate dose) and a MADRS total score .10 
at baseline and, in the opinion of the investigator, had residual 
symptoms that may have benefited from pharmacologic 
modification. De novo patients were also required to be cur-
rently taking antidepressant therapy at an adequate dose for 
a minimum of six weeks by the end of the screening phase. 
In addition to antidepressant therapies permitted in rollover 
patients, de novo patients were also permitted to be receiv-
ing mirtazapine, bupropion, bupropion sustained-release, 
bupropion extended-release, or duloxetine.
Both rollover and de novo patients were excluded if 
they had a current Axis I diagnosis of delirium, dementia, 
amnestic or other cognitive disorder, schizophrenia or other 
psychotic disorder, bipolar I or II disorder, eating disorder, 
or a clinically significant current Axis II diagnosis of border-
line, antisocial, paranoid, schizoid, schizotypal, or histrionic 
personality disorder. Patients who posed a suicide risk were 
also excluded.
All subjects were required to provide written informed 
consent to participate and to be willing to discontinue all 
prohibited psychotropic medication (see below). The study 
was conducted in accordance with the Declaration of Hel-
sinki, and the ethics committee at each site approved the 
protocol.
study treatments
All rollover patients continued to receive their antidepressant 
therapy at the final prescribed dose in the previous trial in 
accordance with current product labeling, ie, escitalopram 
10–20 mg/day, fluoxetine 20–40 mg/day, paroxetine con-
trolled-release 37.5–50 mg/day (paroxetine 20–40 mg/day 
could be substituted if paroxetine controlled-release was 
not available), sertraline 100–150 mg/day, or venlafaxine 
extended-release 150–225 mg/day. De novo patients were 
permitted to receive these antidepressant therapies but could 
also receive bupropion sustained-release 300–400 mg/day, 
bupropion extended-release 150–450 mg/day, bupropion 
300–450 mg/day, duloxetine 40–60 mg/day, or mirtazapine 
15–45 mg/day. All patients were required to continue on their 
initial antidepressant therapy treatment and were not allowed 
to switch antidepressant medications during the course of 
open-label treatment. Dose adjustment of antidepressant 
therapy during the open-label treatment period was permitted 
for optimal therapeutic effect within the recommended dose 
range, although dose adjustment of antidepressant therapy 
should not be made within the same week as   aripiprazole 
dose adjustment. Concomitant use of psychotropic agents 
(neuroleptics, anticonvulsants, antidepressants [other 
than continued antidepressant therapy], mood stabilizers, 
opioid analgesics, stimulants and barbiturates [except for 
migraine]) were prohibited during the study. Treatment of 
extrapyramidal symptoms (benztropine #6 mg/day, propra-
nolol #120 mg/day) was also permitted during the study 
except within 12 hours prior to administration of movement 
rating scales. Clinically appropriate use of benzodiazepines 
and other hypnotics was permitted during the study (eg, 
diazepam, lorazepam, zolpidem, and zaleplon).
All patients, regardless of whether they received aripip-
razole in the prior double-blind studies, started open-label, 
adjunctive treatment with aripiprazole 5 mg/day. If the 5 mg 
dose was well tolerated, the dose was increased to 10 mg/day 
at the end of week 1. The target dose of aripiprazole was 
10 mg/day. Dose adjustments were made based on the clini-
cal judgment of the investigator with respect to tolerability 
and therapeutic efficacy within the range 2–30 mg/day for 
patients receiving venlafaxine extended-release, escitalo-
pram, mirtazapine or sertraline; or 2–15 mg/day for patients 
on fluoxetine, paroxetine, duloxetine, or bupropion (all 
CYP2D6 inhibitors).
Assessments and statistical analyses
Subjects had study visits at the end of weeks 1, 2, 4, 6, 8, 14, 20, 
26, 32, 38, 44, and 52 during open-label treatment or at study 
termination. Safety was evaluated by monitoring of adverse 
events and vital signs (at each study visit), body weight (weeks 
26 and 52,) and a 12-lead electrocardiogram (weeks 8, 26, 
and 52). In addition, extrapyramidal symptoms were evalu-
ated using the Simpson-Angus Scale (SAS),20 and Barnes 
Akathisia Clinical Assessment (BARS)21 at weeks 4, 8, 14, 26, 
38, and 52, and the Abnormal Involuntary Movement Scale 
(AIMS)22 at weeks 4, 8, 14, 20, 26, 32, 38, 44, and 52.
Laboratory tests, including fasting metabolic param-
eters, were conducted at open-label treatment weeks 8, 26, 
38, and 52. Metabolic changes were assessed by mean and 
median change from baseline to endpoint in fasting levels of 
total cholesterol, high-density lipoprotein (HDL) cholesterol, 
low-density lipoprotein (LDL) cholesterol, triglycerides, and 
plasma glucose.
Efficacy was assessed at every study visit using the 
Clinical Global Impression-Severity of Illness (CGI-S) rat-
ing scale (1, normal, not at all ill; 2, borderline mentally ill; 
3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely 
ill; or 7, extremely ill).19 No other efficacy assessments were 
conducted.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Safety analyses included all patients who received at least 
one dose of open-label study medication (safety sample), 
whereas efficacy analyses included all patients in the safety 
sample who had at least one CGI-S assessment in the open-
label treatment phase (efficacy sample). All analyses were 
based on the last observation carried forward or observed 
case datasets.
For patients who had received aripiprazole during weeks 
8–14 in the previously completed double-blind studies 
(aripiprazole rollover patients), baseline for assessment of 
adverse events, discontinuation due to adverse events, weight, 
metabolic measures, and extrapyramidal symptoms were 
defined at week 8 during the short-term trial (ie, prior to the 
first aripiprazole exposure). Thus, the maximum duration of 
aripiprazole treatment for rollover patients was 58 weeks (six 
weeks of double-blind aripiprazole treatment plus 52 weeks of 
open-label treatment). Demographic and disposition data for 
aripiprazole rollover patients used assessments from the week 
14 visit from the previous study as the baseline measurement. 
For de novo and placebo rollover patients, baseline was defined 
using measurements from the start of aripiprazole treatment. 
Summary statistics for safety data are presented, including 
mean and standard deviation for continuous variables, and 
frequency and percent frequency for categorical variables. 
Rating scale scores are presented as mean change from base-
line. No formal statistical testing was planned.
Results
Patient population and treatment
In total, 1076 patients (rollover, n = 706; de novo, n = 370) pro-
vided informed consent for study participation, of whom 1002 
entered the open-label treatment phase (rollover, n = 706; de 
novo, n =  296). Patient disposition is shown in Figure 1 and 
the characteristics of patients included in the safety analyses 
are shown in Table 1. In total, 323 patients (32.2%) completed 
52 weeks of open-label treatment; completion rates were 
similar between the rollover and de novo groups (Figure 1). 
Overall, the most common reasons for withdrawal from the 
open-label treatment phase were adverse events (23.0%), 
lack of efficacy/relapse (13.5%), and withdrawal of consent 
(12.5%). Time to discontinuation of aripiprazole due to any 
reason during open-label treatment is shown in Figure 2.
Treatment and dosing
The distribution of antidepressant therapy at study endpoint 
(n = 984) was consistent with the distribution at open-label 
study baseline and was as follows: escitalopram, n = 275 
(27.7%); venlafaxine extended-release, n = 249 (25.1%); 
sertraline, n = 171 (17.2%); fluoxetine, n = 143 (14.4%); 
paroxetine controlled-release, n = 61 (6.1%); paroxetine, 
n = 29 (2. 9%); bupropion extended-release, n = 35 (3.5%); 
bupropion sustained-release, n = 11 (1.1%); duloxetine, n = 7 
(0.7%); and mirtazapine, n = 3 (0.3%).
At endpoint (n = 987), the mean dose of aripiprazole 
was 10.1 mg/day for the total population. During the last 
four-weekly dosing interval during the open-label phase 
(open-label treatment weeks 48–52, n = 320), the distribution 
of adjunctive aripiprazole dosing was as follows: 2 mg/day, 
10.9%; 5 mg/day, 25.6%; 10 mg/day, 28.8%; 15 mg/day, 
20.3%; 20 mg/day, 7.2%; and .20 mg/day, 7.2%.
The most commonly used (.5% of patients) concomitant 
central nervous system medications during open-label treatment 
were other analgesics and antipyretics (57.0%), anticholinergics 
(10.6%), opioids (9.2%), hypnotics and sedatives (7.5%), and 
anxiolytics (7.2%). Overall, 15.2% of patients received con-
comitant medication for the potential treatment of extrapyrami-
dal symptoms. These included propranolol (5.3%), amantadine 
(0.1%), benztropine (10.6%), and trihexyphenidyl (0.1%).
Adverse events
During long-term treatment, 931 (93.7%) patients experienced 
at least one adverse event. Treatment-emergent adverse events 
that occurred at an incidence $10% are shown in Table 2. The 
most common (.15% of the total population) adverse events 
with long-term adjunctive aripiprazole treatment were akath-
isia (26.2%), fatigue (18.0%), and weight increase (17.1%). 
The majority (75.2%) of treatment-emergent adverse events 
were mild or moderate in nature.
Overall, 226 (22.7%) patients in the safety sample dis-
continued study treatment due to adverse events; the rate of 
discontinuation was 23.7% for aripiprazole rollover patients 
and 22.4% for the placebo rollover/de novo patients. The 
most common adverse events leading to discontinuation 
(.1% of total population) were weight increase (3.3%), 
akathisia (3.3%), somnolence (2.0%), anxiety (1.7%), fatigue 
(1.7%), and sedation (1.1%); no other adverse events resulted 
in discontinuation of more than 1% of patients.
The incidence of serious adverse events was 4.0%; five 
serious adverse events occurred in two placebo rollover/
de novo patients during long-term treatment (suicidal ideation, 
depression, chest pain, myocardial infarction, and intentional 
overdose); cellulitis, cholecystitis, and pneumonia were each 
also experienced by two patients (one placebo rollover/de 
novo patient and one aripiprazole rollover patient). There were 
no reports of neuroleptic malignant syndrome, completed 
suicide, or death due to other causes in this study.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Rollover patients entered open- 
label treatment : n = 706
Discontinued: n = 202 (73%) 
Lack of efficacy: n = 50 (18%)
Adverse event: n = 66 (24%) 
Withdrew consent: n = 43 (16%) 
Lost to follow-up: n = 29 (11%) 
Poor/Non-compliance: n = 10
(4%)
No longer meets study criteria: 
n = 4 (1%)
Completed:
n = 75 (27%) 
Discontinued: n = 279 (65%) 
Lack of efficacy: n = 57 (13%)
Adverse event: n = 90 (21%) 
Withdrew consent: n = 47 (11%) 
Lost to follow-up: n = 46 (11%) 
Poor/Non-compliance: n=19
(4%) 
No longer meets study criteria:
n=6 (1%) 
Other: n = 14 (3%)
Completed: 
n=150 (35%)
Discontinued: n = 198 (67%) 
Lack of efficacy: n = 28 (10%)
Adverse event: n = 74 (25%) 
Withdrew consent: n = 35 (12%) 
Lost to follow-up: n = 34 (12%) 
Poor/Non-compliance: n = 10
(3%) 
No longer meets study criteria:
n = 12 (4%) 
Other: n = 5 (2%)
Completed: 
n = 98 (33%)
De novo Patients Enrolled: n = 370
Baseline
failures: n = 74 
Open-label
baseline
Aripiprazole: n = 296 Aripiprazole: n = 429 Aripiprazole: n = 277
Double-blind
study baseline
(week 8)  
treatment 
assignment
Aripiprazole:
n = 277
Placebo
(Phase B+)a: 
n = 145
Placebo:
n = 284 
Figure 1 enrollment, randomization, and disposition of patients. 
Notes: Shaded boxes represent first aripiprazole dosing; aPatients in Phase B+ were antidepressant therapy responders at week 8 who received placebo for an additional 
six weeks.
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Figure 2 Time to discontinuation of aripiprazole due to any reason during open-
label treatment, safety sample.*
Note: *Aripiprazole rollover patients had been exposed to aripiprazole for six weeks 
prior to open-label treatment.
Table  1  Open-label  baselinea  demographic  characteristics 
(safety sample)
Demographic n = 994
Age (years), mean (sD) 45.8 (11.3)
gender, n (%) female 658 (66.2)
race, n (%)
  White 906 (91.1)
  Black 62 (6.2)
  Asian 9 (0.9)
  Other 17 (1.7)
Weight (kg), mean (sD)b 88.5 (22.6)
BMi (kg/m2), mean (sD)c 31.2 (7.9)
Distribution, n (%)c
BMi # 24 (normal/underweight) 208 (21.0)
BMi 25-29 (overweight) 292 (29.4)
BMi $ 30 (obese) 492 (49.6)
recurrent episode, n (%)b 776 (78.1)
MADrs total score, mean (sD) 20.2 (9.0)
Notes: aFor rollover patients, assessments from the week 14 visit from the previous 
study served as the baseline measurement; for de novo patients, baseline was defined 
using the measurements from the start of the open-label study; bn = 993; cn = 992. 
Abbreviations:  sD,  standard  deviation;  BMi,  body  mass  index;  MADrs, 
Montgomery-Åsberg Depression scale.
extrapyramidal symptoms
The rates of reported extrapyramidal symptom-related 
adverse events were as follows: dystonic events, 4.0%; 
parkinsonian events, 10.6%; akathisia events (ie, akathisia, 
psychomotor hyperactivity), 26.5%; dyskinetic events, 1.8%; 
and residual events, 2.2%. Akathisia occurred in 26.2% 
of this open-label population (placebo rollover/de novo 
patients, 24.0%; aripiprazole rollover patients, 31.8%) and the 
  majority of cases had their onset within the first six weeks of 
treatment. Akathisia led to discontinuation in 3.3% of study 
patients. There were small mean changes from baseline in 
the AIMS, SAS, and BARS scores; mean change from base-
line to week 52 (last observation carried forward) was 0.06 
for the AIMS total score (mean baseline 0.07), 0.17 points 
for the SAS (mean baseline 10.32), and 0.11 for the BARS 
(mean baseline 0.15).
Four spontaneous reports of possible tardive   dyskinesia 
were submitted during the study (0.4%); all the patients Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 2 Treatment-emergent adverse events ($10% of patients, safety sample)
Adverse event, n (%) Placebo rollover/de novo 
patients (n = 720)
Aripiprazole rollover 
patients (n = 274)
Total (n = 994)
Akathisia 173 (24.0) 87 (31.8) 260 (26.2)
Fatigue 135 (18.8) 44 (16.1) 179 (18.0)
Weight increase 131 (18.2) 39 (14.2) 170 (17.1)
restlessness 98 (13.6) 44 (16.1) 142 (14.3)
insomnia 93 (12.9) 29 (10.6) 122 (12.3)
somnolence 103 (14.3) 33 (12.0) 136 (13.7)
headache 93 (12.9) 24 (8.8) 117 (11.8)
Upper respiratory tract infection 68 (9.4) 38 (13.9) 106 (10.7)
Nausea 77 (10.7) 18 (6.6) 95 (9.6)
Dizziness 73 (10.1) 18 (6.6) 91 (9.2)
Note: reporting of adverse events for aripiprazole rollover patients includes any adverse events that may have occurred with aripiprazole treatment during the previous 
double-blind study period.
involved were receiving aripiprazole adjunctive to 
  escitalopram. Interventions to manage tardive dyski-
nesia included dose reduction (n = 2) and drug discon-
tinuation (n = 2). In all four cases, highest AIMS total 
scores were #4, and the symptoms completely resolved 
within 45 days of discontinuing adjunctive aripiprazole 
treatment.
Body weight
At week 26/32 (n = 491), the mean change in body weight 
from baseline (observed case) was 3.6 kg (placebo rollover/
de novo patients, 3.4 kg; aripiprazole rollover patients, 
4.3 kg). For the patients who completed 52/58 weeks of 
open-label adjunctive treatment (n = 303), the mean change 
in body weight over time showed that most weight gain 
occurred in the first 26–32 weeks on treatment. At week 
26/32, the mean change in body weight was 4.0 kg, and at 
week 52/58 was 4.4 kg (placebo rollover/de novo patients, 
3.9 kg at week 26, and 4.3 kg at week 52; aripiprazole 
rollover patients, 4.4 kg at week 32 and 4.9 kg at week 
58). Mean change in body weight for aripiprazole rollover 
patients completing the study at week 6 was 1.8 kg. For 
aripiprazole rollover patients who had clinically significant 
weight gain ($7%) at week 6, the mean change in body 
weight from baseline (observed case) was 8.7 kg at week 32 
and 8.5 kg at week 58 (both n = 7). In aripiprazole rollover 
patients without clinically significant weight gain at week 
6, mean change in body weight from baseline (observed 
case) was 4.0 kg (n = 106) and 4.5 kg (n = 64) at weeks 32 
and 58, respectively.
Clinically significant weight gain ($7%) occurred in 
28.0% of patients (based on a last observation carried forward 
analysis) and 36.6% of subjects who completed the study 
(observed case analysis).
Metabolic effects
Figure 3 shows the mean change in fasting metabolic param-
eters from adjunctive aripiprazole baseline, by treatment 
period, for patients who continued to receive treatment 
(observed case analysis). National Cholesterol Education 
Program (NCEP)-defined cut-offs (see Figure 3) show that, 
on average, LDL, HDL, and glucose levels remained within 
normal limits. Baseline levels of cholesterol were higher, but 
tended to decrease over the 52-week exposure to aripipra-
zole. Baseline triglyceride levels were also above the normal 
150 mg/dL criterion and remained above baseline throughout 
the course of aripiprazole treatment. Overall, there were 
no clinically important findings in the mean changes from 
baseline in fasting cholesterol, HDL, LDL, triglycerides, or 
glucose. For adjunctive aripiprazole exposure .46 weeks, 
the median change (range) in fasting metabolic parameters 
from adjunctive aripiprazole baseline were as follows: fasting 
cholesterol (n = 264), -4.0 (-154.0 to 90.0) mg/dL; fasting 
HDL (n = 264), -5.0 (-85.0 to 24.0) mg/dL; fasting LDL 
(n = 264), 1.0 (-117.0 to 94.0) mg/dL; fasting triglycerides 
(n = 264), 8.0 (-385.0 to 354.0) mg/dL, and fasting glucose 
(n = 262), 2.5 (-128.0 to 151.0) mg/dL.
The incidence of treatment-emergent potentially 
clinically relevant abnormalities in fasting total cholesterol 
levels ($240 mg/dL) was 11.9% (n = 33/277) with adjunc-
tive aripiprazole and 13.6% (n = 38/280) with adjunctive 
placebo during placebo-controlled trials and was 19.4% 
(n = 135/697) for a pooled population of patients treated 
with aripiprazole in both the short-term studies and this 
long-term trial. The incidence of treatment-emergent poten-
tially clinically relevant abnormalities in fasting glucose 
levels ($126 mg/dL) was 2.2% (n = 8/358) with adjunctive 
aripiprazole and 2.8% (n = 10/362) with adjunctive placebo 
during placebo-controlled trials, and was 4.9% (n = 44/906) Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Figure 3 Time-course of fasting metabolic mean changes from baseline (observed case analysis). 
Notes: Mean (se) baseline values: fasting total cholesterol (n = 773), 214.6 (1.5) mg/dL; fasting hDL cholesterol (n = 773), 57.8 (0.6) mg/dL; fasting LDL cholesterol (n = 773), 
125.8 (1.3) mg/dL; fasting triglycerides (n = 773), 156.5 (3.9) mg/dL; fasting glucose (n = 769), 93.5 (0.6) mg/dL. Dashed line and arrows represents abnormal lipid values 
(NCEP-defined criteria) and glucose levels (ADA criteria). Laboratory evaluations were performed at weeks 6, 14, 32, 44, and 58 for aripiprazole rollover patients, and weeks 
8, 26, 38, and 52 for placebo rollover/de novo patients. For patients who had received aripiprazole in the previous double-blind study (aripiprazole rollover patients), baseline 
refers to week 8 scores from double-blind treatment. 
Abbreviations: se, standard error; hDL, high-density lipoprotein; LDL, low-density lipoprotein; NceP, National cholesterol education Program; ADA, American Diabetes 
Association.
for the pooled total population from short-term and long-
term studies.
Vital signs and laboratory findings
The incidence of potentially clinically relevant vital sign 
and electrocardiographic abnormalities, as well as serum 
chemistry, hematology, and electrolyte measurements, was 
low. The exception to this was the incidence of potentially 
clinically relevant prolactin elevations at at least one blood 
draw (13.7%). For a number of these patients, there were rel-
evant prolactin elevations at study baseline and aripiprazole 
treatment was associated with decreased prolactin levels. At 
week 52 (last observation carried forward), patients showed 
a mean decrease of 0.5 ng/dL in serum prolactin levels from 
baseline (12.9 ng/dL).
Efficacy
Mean CGI-S scores over the course of treatment showed sus-
tained improvement in clinical symptoms, regardless of treat-
ment during the double-blind study (Figure 4). At baseline, 
33 patients (10.4%) had a CGI-S score of 1 or 2, indicating 
“normal” or “borderline ill” at adjunctive aripiprazole base-
line, whereas at the end of open-label treatment (week 52/58) 
221 patients (69.7%) had a CGI-S score of 1 or 2.
Discussion
Major depressive disorder is a chronic and recurrent condition 
that often requires patients to receive treatment for prolonged 
periods of time. As such, understanding the long-term toler-
ability profiles of treatments is essential for optimal clinical 
management. In this long-term study, the safety and tolerability 
of aripiprazole augmentation was demonstrated by relatively 
low discontinuation rates due to adverse events (23%) over a 
52–58-week exposure. Furthermore, the adverse event profile 
was consistent with that reported in the short-term, double-
blind, placebo-controlled trials.23 Most adverse events were 
mild or moderate in severity and the incidence of serious 
adverse events was low. The incidence of vital sign/laboratory 
abnormalities was also low, with the exception of prolactin 
elevations. The effect of aripiprazole on prolactin elevation 
is difficult to interpret due to some patients having elevated 
levels at baseline, and a mean overall decrease in prolactin 
levels after treatment with adjunctive aripiprazole. Nonethe-
less, patients should be monitored for signs and symptoms of 
prolactin elevations due to the potential for sexual dysfunction 
and decreased bone mineral density.24 Clinically significant 
weight gain during extended treatment was evident in a sig-
nificant minority of patients, and weight gain was one of the 
most common adverse events with treatment.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Although adjunctive aripiprazole was associated with 
a mean weight gain of 4.4 kg, the relative contribution of 
aripiprazole to weight gain compared with antidepressants 
alone is difficult to determine, because long-term admin-
istration of antidepressant medications is also associated 
with medically relevant weight gain.25–28 For example, 
in one study, patients treated with fluoxetine for at least 
one year experienced a mean weight gain of 3.2 kg, and 
25.4% had a clinically relevant weight gain ($7%).25 
Interestingly, the rate of clinically relevant weight gain 
was similarly high for patients treated with placebo for 
the same duration.25
It is noteworthy that the aripiprazole rollover patients with 
clinically significant weight gain in the first six weeks of treat-
ment experienced greater weight gain than patients without 
early weight gain. The majority of weight gain occurred over 
the first six months of treatment in both groups, suggest-
ing that weight gain plateaus during long-term   treatment. 
Regardless, patients receiving adjunctive aripiprazole over 
the longer term should be monitored for weight gain and 
should be proactively managed should it occur, especially 
given that the relative risk for long-term weight gain is not 
equal across all selective serotonin reuptake inhibitors.10 
Continued treatment in patients experiencing weight gain 
should be based on clinical assessment of the patient in the 
context of benefits and side effects.
Extrapyramidal symptoms and metabolic abnormalities 
are adverse events of great concern for patients taking antipsy-
chotic medications over the long term. Adjunctive aripiprazole 
had minimal effects on blood lipid and glucose levels. There 
were no clinically meaningful increases in mean fasting meta-
bolic parameters over the course of treatment and, on average, 
patients remained within, or slightly above, NCEP-defined 
“normal” limits. Similar shifts to “abnormal” levels of total 
cholesterol or glucose did occur within the first six weeks of 
treatment for patients treated with adjunctive aripiprazole 
and antidepressant monotherapy. Some additional shifts were 
observed over the course of the 52–58-week exposure, yet we 
cannot determine whether the shifts were directly related to 
aripiprazole, the antidepressant, or to the population already 
being overweight and obese at trial entry. Nonetheless, the 
data underscore the need for regular metabolic monitoring 
in patients with depression treated with adjunctive atypical 
antipsychotics. As for extrapyramidal symptoms, in this study, 
the rate of extrapyramidal symptom-related adverse events was 
not substantially different from that observed in the short-term, 
double-blind, placebo-controlled trials.23 The objective move-
ment disorder rating scales, AIMS, BARS, and SAS, did not 
reveal substantial evidence of extrapyramidal symptoms.
There were four spontaneous reports of tardive dyskinesia 
in this study; however, it is important to note that all four cases 
resolved with dose reduction or drug discontinuation. Given 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Study week
M
e
a
n
 
C
G
I
-
S
 
s
c
o
r
e
De novo (n = 285)
Prior placebo (n = 281)
Prior placebo phase B+ (n = 142)
Prior aripiprazole (n = 267)
Week 52
LOCF 
Double-blind 
treatment
−6 −4 −2 024681 01 21 41 61 82 02 22 42 62 83 03 25 2 50 48 46 44 42 40 38 36 34
Figure 4 Mean cgi-s scores by treatment week. 
Notes: Data by study week is from Oc analysis; week 52 LOcF data are also shown. N numbers are week 52 (LOcF); weeks -6 to 0 represents cgi-s scores for 
aripiprazole rollover and placebo rollover patients during the previous double-blind study period; weeks 0 to 52 represent cgi-s scores during open-label treatment. Patients 
in the prior placebo Phase B+ group were ADT responders at week 8 who received placebo for an additional six weeks. 
Abbreviations: cgi-s, clinical global impression-severity of illness scale; Oc, observed case; LOcF, last observation carried forward; ADT, antidepressant therapy.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
311
Long-term aripiprazole augmentation in MDD
that tardive dyskinesia is considered to be a chronic, persis-
tent condition, the resolution of symptoms within 45 days 
of dose reduction or drug discontinuation may suggest that 
these cases of tardive dyskinesia were readily amenable to 
conventional intervention or the reports may have represented 
phenomena other than tardive dyskinesia. Given that tardive 
dyskinesia is a potentially serious adverse event, clinicians 
should remain mindful of the emergence of tardive dyskinesia 
with long-term adjunctive aripiprazole treatment, and take 
steps to manage patients who present with symptoms.
Of note, all patients started at 5 mg/day and were 
  recommended to increase to 10 mg/day at the end of week 1. 
Although akathisia was the most common adverse event 
during long-term treatment, it rarely led to study discon-
tinuation, and generally had its onset early in the course of 
treatment. Consideration of starting at a lower dose, such as 
2 mg, with a slower titration schedule may reduce the inci-
dence of extrapyramidal symptom-related adverse events, 
including akathisia.
Endpoint CGI-S scores suggest that adjunctive aripipra-
zole provides clinically meaningful, persistent efficacy with 
long-term treatment; nearly 70% of subjects who continued 
long-term treatment had a CGI-S score of 1 (normal) or 2 
(borderline ill), indicating that scores are consistent with 
remission from symptoms. Regardless of previous treatment, 
all groups had a comparable mean endpoint score, suggesting 
a stability of effect over time. Also notable is the speed of 
onset of symptom relief. On average, most improvement in 
CGI-S scores occurred in the first month of treatment and 
was sustained over a year of treatment. However, conclusions 
on long-term efficacy of adjunctive aripiprazole treatment 
are limited, because this study was not designed to assess 
the maintenance of effect specifically; a double-blind study 
using a placebo-controlled discontinuation design will be 
necessary in order to establish longer-term efficacy.
The findings of this study are strengthened by the large 
overall patient population with major depressive disor-
der who received adjunctive aripiprazole treatment over 
52–58 weeks of exposure. However, the findings reported 
here should be evaluated with consideration to several 
limitations, such as the open-label study design and the 
lack of a control treatment group, which limits the ability 
to attribute adverse events solely to adjunctive aripiprazole 
treatment because some adverse events may have resulted 
from the long-term use of the antidepressant therapies. It 
should also be considered that all patients were retitrated 
to aripiprazole 5 mg/day at entry into open-label treatment; 
this may have had an impact on the occurrence of adverse 
events for patients who were previously receiving a stable 
dose of aripiprazole during the parent studies. The impact of 
any effect of   retitration on adverse events was not evaluated. 
Finally, patients benefiting from aripiprazole augmentation 
in this study were receiving a variety of different antidepres-
sants, which were assigned based on investigator judgment. 
As such, the relative   benefit of one antidepressant agent over 
the other has not been evaluated.
Conclusion
Overall, aripiprazole augmentation was well tolerated, 
with an acceptable long-term safety and tolerability profile 
in patients with major depressive disorder who had not 
responded to treatment with one or more antidepressant 
therapies. Common adverse events to consider during the 
long-term use of adjunctive aripiprazole for the treatment of 
major depressive disorder include weight gain and akathisia, 
although these events seldom led to treatment discontinua-
tion in this study.
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